Zantac Lawsuit


Researching drug company and regulatory malfeasance for over 16 years
Humanist, humorist

Thursday, January 07, 2010

JAMA analysis questions antidepressant drug benefits


Image: krispycanadian.files.wordpress.com




07 January 2010
Another meta-analysis has cast doubt on the effectiveness of drug therapy as a strategy for tackling depression, specifically the less severe forms of the disease.

The study published in the Journal of the American Medical Association (JAMA) found that in six trials involving treatment with paroxetine (GlaxoSmithKline’s Paxil, Seroxat), the genericised imipramine or placebo, the benefits of medication versus placebo were “non-existent to negligible” among patients with mild, moderate or even severe symptoms of depression, whereas in patients with very severe depression the effects were substantial.

Read more here


Fid

ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING

No comments:


Please contact me if you would like a guest post considered for publication on my blog.